CytRx arimoclomol begins Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CytRx is initiating a Phase II trial of its amyotrophic lateral sclerosis treatment arimoclomol, the firm says Sept. 22. CytRx received notification from FDA Sept. 21 regarding a clinical hold on the development program for the molecular chaperone activator announced last July (1Pharmaceutical Approvals Monthly August 2005, In Brief). The double-blind, placebo-controlled trial will enroll 80 patients from eight to ten U.S. centers. Primary endpoints are safety and tolerability; secondary endpoints include the revised ALS Functional Rating Scale. A second Phase II trial in 300 patients is slated to begin "soon after completion" of the present trial. CytRx announced FDA's decision to grant arimoclomol fast-track status Sept. 26...
You may also be interested in...
CytRx arimoclomol clinical hold
CytRx hopes to begin a Phase II trial of its amyotrophic lateral sclerosis treatment arimoclomol by the end of 2005 based on communications from FDA regarding the agency's clinical hold on the trial, the Los Angeles firm says Aug. 10. FDA cited two actions required to lift the hold: submission of existing clinical information on CytRx' related small molecule agent bimoclomol, "which has been more extensively tested for safety in humans than arimoclomol"; and a protocol amendment to the study "to add specific clinical tests to be administered to patients enrolled in the study." CytRx announced the hold July 21...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.